Colorectal Cancer

Superior overall survival was induced with sequencing regorafenib (Stivarga) before cetuximab (Erbitux) compared with the reverse sequence in patients with metastatic colorectal cancer following failure of standard chemotherapy, according to findings from the phase II REVERCE study presented at the 2018 Gastrointestinal Cancers Symposium.

According to 2 analyses presented at the 2018 Gastrointestinal Cancers Symposium, data from the CheckMate-142 study support the use of nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) for the treatment of patients with previously treated DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer.

According to findings reported during the 2018 Gastrointestinal Cancers Symposium, a weekly dose-escalation strategy of regorafenib (Stivarga) beginning at 80 mg and ending at 160 mg was found to be superior than the previously standard starting dose of 160 mg in patients with metastatic colorectal cancer.

A novel circulating tumor cell assay has demonstrated a high accuracy of up to 88% for detecting early-stage colorectal cancer, according to the results of a prospective study from Taiwan released ahead of a presentation at the 2018 Gastrointestinal Cancers Symposium in San Francisco, California. The study marks the first to show a high sensitivity for detecting precancerous lesions, as prior studies tended to identify later-stage CRCs.

Cathy Eng, MD, FACP, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing clinical trials in the <em>BRAF</em>-mutant colorectal cancer patient population.

John L. Marshall, MD,&nbsp;recaps some of the biggest CRC advancements of 2017, and explained what those successes mean for the treatment paradigm moving forward.

According to findings from the phase III TERRA trial published in the <em>Journal of Clinical Oncology, </em>previously treated Asian patients with metastatic colorectal cancer saw a significant survival benefit with TAS-102&nbsp;(trifluridine and tipiracil; Lonsurf) compared with placebo.

According to the results of the randomized phase III&nbsp;AXEPT clinical trial, a chemotherapy doublet has proved noninferior to treatment with standard FOLFIRI (folinic acid [leucovorin], fluorouracil [5-FU], and irinotecan) for patients with previously treated metastatic colorectal cancer (mCRC).¹

John L. Marshall, MD,&nbsp;chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the progress that has been made with immunotherapy in the treatment of colorectal cancer.

Michael A. Morse, MD,&nbsp;explained his treatment decisions in 1 patient with metastatic colorectal cancer who progresses and requires second-line treatment during a&nbsp;recent <em>Targeted Oncology</em>&nbsp;live case-based peer perspectives dinner.

Hans-Joachim Schmoll, MD,&nbsp;discusses updated CHARTA findings, the current role of chemotherapy in patients with metastatic CRC, and his predictions for the future CRC treatment landscape.

Leonard Saltz, MD,&nbsp;highlights the current go-to therapies and overarching questions for mCRC treatment.

Shubham Pant, MD,&nbsp;discusses therapeutic options for patients with metastatic CRC, while&nbsp;stressing the importance of clinical trials as an avenue to establish more novel treatment decisions in this setting.

John L. Marshall, MD,&nbsp;chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses when to order next-generation sequencing for a patient with metastatic colon cancer.

Alan P. Venook, MD, recently discussed 2 cases of patients with colorectal cancer, and the treatment treatment considerations and decisions he would make when treating these patients. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, and professor, Department of Medicine, University of California San Francisco, discussed these cases during a&nbsp;<em>Targeted Oncology</em>&nbsp;live case-based peer perspectives dinner.<br /> &nbsp;

Tim G. Larson, MD, discusses&nbsp;emerging data involving immunotherapy for patients with microsatellite instability (MSI)/microsatellite stable (MSS) CRC and highlights some of the identified molecular mutations in patients with CRC.

The use of targeted therapies in colon cancer has become increasingly important, with several options available for clinicans to choose between. In a review of recent updates incorporating molecularly targeted therapy use in the National Comprehensive Cancer Network guidelines, the evidence for these new recommendations are detailed in support of their use in patients with colon cancer.

A. David McCollum, MD, discusses&nbsp;the optimal management of CRC in the first-line setting and the ongoing research with checkpoint inhibitors designed to benefit larger groups of patients.<br /> &nbsp;

Cathy Eng, MD, FACP, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses choosing between TAS-102 (Lonsurf) and regorafenib (Stivarga) in colorectal cancer.

John L. Marshall, MD, Director, The Ruesch Center for the Cure of Gastrointestinal Cancers&nbsp;at Georgetown Lombardi Comprehensive Cancer Center, discusses decision making in the frontline treatment of patients with metastatic colon cancer.

Richard Kim, MD, recently shared the treatment considerations and decisions he makes when treating patients with metastatic colorectal cancer, including the role of mutation testing and location of the tumor. Kim, associate professor of oncology, Moffitt Cancer Center, explained his treatment decisions based on 2 case scenarios during a&nbsp;<em>Targeted Oncology</em>&nbsp;live case-based peer perspectives dinner.

Mike Cusnir, MD, co-director of gastrointestinal malignancies, Mount Sinai Medical Center, recently discussed the cases of 2 patients with metastatic colorectal cancer (mCRC).<br /> &nbsp;

Hans-Joachim Schmoll, MD, discusses&nbsp;updated CHARTA findings, the current role of chemotherapy in patients with metastatic CRC, and his predictions for the future CRC treatment landscape.

Cathy Eng, MD, discussed optimizing sequencing beyond disease progression in CRC

Johanna Bendell, MD, discusses&nbsp; the current and emerging treatment landscape of immunotherapy for patients with CRC.